Français

Decisions around deprescribing can be very difficult. Few evidence-based guidelines exist to support safe deprescribing for specific classes of medication.

Researchers from the Bruyère Research Institute and the Ontario Pharmacy Research Collaboration developed evidence-based guidelines for deprescribing.

Each guideline is summarized in an easy-to-use algorithm and information brochure. These algorithms can help health care professionals safely stop or reduce medications for specific drug classes.

Click below to access each algorithm, guideline and information brochure:

Proton Pump Inhibitor (PPI)

• Proton Pump Inhibitor deprescribing algorithm

• Proton Pump Inhibitor evidence-based deprescribing guideline

• Whiteboard video on using the Proton Pump Inhibitor deprescribing algorithm

Antihyperglycemic

• Antihyperglycemic deprescribing algorithm

• Antihyperglycemic deprescribing guideline

• Whiteboard video on using the Antihyperglycemic deprescribing algorithm

Antipsychotic

• Antipsychotic deprescribing algorithm

• Antipsychotic deprescribing guideline

• Whiteboard video on using the antipsychotic deprescribing algorithm

Benzodiazepine and z-drugs

• Benzodiazepine receptor agonist deprescribing algorithm

• Benzodiazepine deprescribing guideline

• Whiteboard video on using the benzodiazepine deprescribing algorithm

Cholinesterase Inhibitors (ChEIs) and Memantine

• Cholinesterase inhibitor and memantine deprescribing algorithm

• Cholinesterase inhibitors and memantine deprescribing guideline

Each algorithm provides evidence for the benefits and harms of continuing or deprescribing the medications. The algorithms also take into account patient preferences and values surrounding deprescribing, together with practical advice on how to implement deprescribing. The algorithms are also available on the website deprescribing.org, which contains useful tools and information for healthcare providers.

Do you want to know how the algorithms were created? Watch the video below: